{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:30:44Z","timestamp":1784716244158,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["ZIADK31117"],"award-info":[{"award-number":["ZIADK31117"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["ZIADK75013"],"award-info":[{"award-number":["ZIADK75013"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11302-020-09715-0","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T21:02:49Z","timestamp":1595883769000},"page":"367-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Design and in vivo activity of A3 adenosine receptor agonist prodrugs"],"prefix":"10.1007","volume":"16","author":[{"given":"R. Rama","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoumou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip K.","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren C.","family":"Podszun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Rotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Salvemini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-1493","authenticated-orcid":false,"given":"Kenneth A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"9715_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J (2016) Purinergic regulation of the immune system. Nat Rev Immunol 16:177\u2013192","journal-title":"Nat Rev Immunol"},{"key":"9715_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"KA Jacobson","year":"2006","unstructured":"Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nature Rev Drug Disc 5:247\u2013264","journal-title":"Nature Rev Drug Disc"},{"key":"9715_CR3","doi-asserted-by":"publisher","unstructured":"Varani K, Vincenzi F, Merighi S, Gessi S, Borea PA (2017) Biochemical and pharmacological role of A1 adenosine receptors and their modulation as novel therapeutic strategy. Adv Exp Med Biol - Protein Reviews pp. 193\u2013232, DOI https:\/\/doi.org\/10.1007\/5584_2017_61","DOI":"10.1007\/5584_2017_61"},{"key":"9715_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/med.21456","volume":"38","author":"KA Jacobson","year":"2017","unstructured":"Jacobson KA, Merighi S, Varani K, Borea PA, Baraldi S, Tabrizi MA, Romagnoli R, Baraldi PG, Ciancetta A, Tosh DK, Gao ZG, Gessi S (2017) A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy. Med Res Rev 38:1031\u20131072","journal-title":"Med Res Rev"},{"key":"9715_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/med.21344","volume":"35","author":"D Preti","year":"2015","unstructured":"Preti D, Baraldi PG, Moorman AR, Borea PA, Varani K (2015) History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents. Med Res Rev 35:790\u2013848. https:\/\/doi.org\/10.1002\/med.21344","journal-title":"Med Res Rev"},{"key":"9715_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bcp.2014.05.008","volume":"90","author":"ZG Gao","year":"2014","unstructured":"Gao ZG, Balasubramanian R, Kiselev E, Wei Q, Jacobson KA (2014) Probing biased\/partial agonism at the G protein-coupled A2B adenosine receptor. Biochem Pharmacol 90:297\u2013306","journal-title":"Biochem Pharmacol"},{"key":"9715_CR7","doi-asserted-by":"publisher","first-page":"2310970","DOI":"10.1155\/2018\/2310970","volume":"2018","author":"S Cohen","year":"2018","unstructured":"Cohen S, Barer F, Itzhak I, Silverman MH, Fishman P (2018) Inhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist piclidenoson. J Immunol Res 2018:2310970","journal-title":"J Immunol Res"},{"key":"9715_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/1745-7580.1000087","volume":"11","author":"RM Stoilov","year":"2014","unstructured":"Stoilov RM, Licheva RN, Mihaylova MK, Reitblat T, Dimitrov EA, Shimbova KM, Bhatia G, Pispati A, Gurman-Balbir A, Bagaria BR, Oparanov BA, Fishman S, Harpaz Z, Farbstein M, Cohen S, Bristol D, Silverman MH, Fishman P (2014) Therapeutic effect of oral CF101 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II study. Immunome Res 11:1","journal-title":"Immunome Res"},{"key":"9715_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2012-0211","volume":"18","author":"M Stemmer","year":"2013","unstructured":"Stemmer M, Benjaminov F, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I\/II, open-label, dose-escalation study. Oncologist 18:25\u201326","journal-title":"Oncologist"},{"issue":"5","key":"9715_CR10","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.3892\/mmr.2016.5746","volume":"14","author":"G Ohana","year":"2016","unstructured":"Ohana G, Cohen S, Rath-Wolfson L, Fishman P (2016) A3 adenosine receptor agonist, CF102, protects against hepatic ischemia\/reperfusion injury following partial hepatectomy. Mol Med Rep 14(5):4335\u20134341","journal-title":"Mol Med Rep"},{"issue":"8","key":"9715_CR11","first-page":"931","volume":"15","author":"M David","year":"2016","unstructured":"David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV, Cosgarea MR, Morariu HS, Michael Z, Cristodor P, Nica C, Silverman MH, Bristol DR, Harpaz Z, Farbstein M, Cohen S, Fishman P (2016) Treatment of plaque-type psoriasis with oral CF101: data from a phase II\/III multicenter, randomized, controlled trial. J Drugs Dermatol 15(8):931\u2013938","journal-title":"J Drugs Dermatol"},{"key":"9715_CR12","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s10067-016-3202-4","volume":"35","author":"P Fishman","year":"2016","unstructured":"Fishman P, Cohen S (2016) The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol 35:2359\u20132362","journal-title":"Clin Rheumatol"},{"key":"9715_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cellimm.2009.03.020","volume":"258","author":"A Ochaion","year":"2009","unstructured":"Ochaion A, Bar-YehudaS CS, Barer F, Patoka R, Amital H, Reitblat T, Reitblat A, Ophir J, Konfino I, Chowers Y, Ben-Horin S, Fishman P (2009) The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn\u2019s disease. Cell Immunol 258:115\u2013122","journal-title":"Cell Immunol"},{"key":"9715_CR14","doi-asserted-by":"publisher","first-page":"R197","DOI":"10.1186\/ar3527","volume":"13","author":"K Varani","year":"2011","unstructured":"Varani K, Padovan M, Vincenzi F, Vincenzi F, Targa M, Trotta F, Govoni M, Borea PA (2011) A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther 13:R197. https:\/\/doi.org\/10.1186\/ar3527","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"9715_CR15","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3892\/ijmm.2019.4364","volume":"44","author":"P Fishman","year":"2019","unstructured":"Fishman P, Cohen S, Itzhak I, Amer J, Salhab A, Barer F, Safadi R (2019) The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice. Int J Mol Med 44(6):2256\u20132264. https:\/\/doi.org\/10.3892\/ijmm.2019.4364","journal-title":"Int J Mol Med"},{"key":"9715_CR16","unstructured":"Fishman P, Cohen SA (2017) A3 adenosine receptor ligand for use in treating ectopic fat accumulation. WO2017090036 (A1)"},{"key":"9715_CR17","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.biochi.2013.09.003","volume":"95","author":"CG Miao","year":"2013","unstructured":"Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, Lv XW, Jin Y, Li J (2013) Wnt signaling in liver fibrosis: Progress, challenges and potential directions. Biochimie 95:2326\u20132335","journal-title":"Biochimie"},{"key":"9715_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/bph.13446","volume":"173","author":"K Janes","year":"2016","unstructured":"Janes K, Symons-Liguori AM, Jacobson KA, Salvemini D (2016) Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. Br J Pharmacol 173:1253\u20131267","journal-title":"Br J Pharmacol"},{"key":"9715_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11302-015-9459-2","volume":"11","author":"DK Tosh","year":"2015","unstructured":"Tosh DK, Padia J, Salvemini D, Jacobson KA (2015) Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signal 11:371\u2013387","journal-title":"Purinergic Signal"},{"key":"9715_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/j.pain.0000000000001177","volume":"159","author":"C Wahlman","year":"2018","unstructured":"Wahlman C, Doyle T, Little JW, Luongo L, Janes K, Chen Z, Espostio E, Tosh DK, Cuzzocrea S, Jacobson KA, Salvemini D (2018) Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels via astrocyte-dependent mechanisms. Pain 159:1025\u20131034","journal-title":"Pain"},{"key":"9715_CR21","doi-asserted-by":"publisher","first-page":"9901","DOI":"10.1021\/jm501021n","volume":"57","author":"DK Tosh","year":"2014","unstructured":"Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski E, Auchampach J, Salvemini D, Jacobson KA (2014) In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. J Med Chem 57:9901\u20139914","journal-title":"J Med Chem"},{"key":"9715_CR22","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1021\/jm300396n","volume":"55","author":"DK Tosh","year":"2012","unstructured":"Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA (2012) Structure-guided design of A3 adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem 55:4847\u20134860","journal-title":"J Med Chem"},{"key":"9715_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrd.2018.46","volume":"17","author":"J Rautio","year":"2018","unstructured":"Rautio J, Meanwell N, Di L, Hageman MJ (2018) The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 17:559\u2013587","journal-title":"Nat Rev Drug Discov"},{"issue":"541","key":"9715_CR24","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Sch\u00e4fer A, Dinnon KH III, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12(541):eabb5883. https:\/\/doi.org\/10.1126\/scitranslmed.abb5883","journal-title":"Sci Transl Med"},{"key":"9715_CR25","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1135\/cccc20060912","volume":"71","author":"P Besada","year":"2006","unstructured":"Besada P, Mamedova LK, Palaniappan KK, Gao ZG, Joshi BV, Jeong LS, Civan MM, Jacobson KA (2006) Nucleoside prodrugs of A3 adenosine receptor agonists and antagonists. Collect Czechoslov Chem Commun 71:912\u2013928","journal-title":"Collect Czechoslov Chem Commun"},{"key":"9715_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","volume":"33","author":"GJ Bennett","year":"1988","unstructured":"Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87\u2013107","journal-title":"Pain"},{"key":"9715_CR27","doi-asserted-by":"publisher","unstructured":"Jain S, Tosh DK, Reitman ML, Jacobson KA (2019) Role of A1 and A3 adenosine receptors in whole body glucose metabolism. ADA abstract 280-LB. https:\/\/doi.org\/10.2337\/db19-280-LB","DOI":"10.2337\/db19-280-LB"},{"issue":"5","key":"9715_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/jps.2600570510","volume":"57","author":"LW Dittert","year":"1968","unstructured":"Dittert LW, Caldwell HC, Adams HJ, Irwin GM, Swintosky JV (1968) Acetaminophen prodrugs I. synthesis, physicochemical properties, and analgesic activity. J Pharm Sci 57(5):774\u2013780. https:\/\/doi.org\/10.1002\/jps.2600570510","journal-title":"J Pharm Sci"},{"issue":"1","key":"9715_CR29","doi-asserted-by":"publisher","first-page":"12023","DOI":"10.1038\/srep12023","volume":"5","author":"Q Fu","year":"2015","unstructured":"Fu Q, Wang Y, Ma Y, Zhang D, Fallon JK, Yang X, Liu D, He Z, Liu F (2015) Programmed hydrolysis in designing paclitaxel prodrug for nanocarrier assembly. Sci Rep 5(1):12023. https:\/\/doi.org\/10.1038\/srep12023","journal-title":"Sci Rep"},{"key":"9715_CR30","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1016\/j.bmcl.2009.09.114","volume":"19","author":"L Biasutto","year":"2009","unstructured":"Biasutto L, Marotta E, Bradaschia A, Fallica M, Mattarei A, Garbisa S, Zoratti M, Paradisi C (2009) Soluble polyphenols: synthesis and bioavailability of 3,4\u2032,5-tri (alpha-D-glucose-3-O-succinyl) resveratrol. Bioorg Med Chem Lett 19:6721\u20136724. https:\/\/doi.org\/10.1016\/j.bmcl.2009.09.114","journal-title":"Bioorg Med Chem Lett"},{"key":"9715_CR31","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/molecules16021888","volume":"16","author":"W Wichitnithad","year":"2011","unstructured":"Wichitnithad W, Nimmannit U, Wacharasindhu S, Rojsitthisak P (2011) Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment. Molecules 16:1888\u20131900","journal-title":"Molecules"},{"issue":"2","key":"9715_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/molecules13020348","volume":"13","author":"K Vollmann","year":"2008","unstructured":"Vollmann K, Qurishi R, Hockemeyer J, M\u00fcller CE (2008) Synthesis and properties of a new water-soluble prodrug of the adenosine A2A receptor antagonist MSX-2. Molecules 13(2):348\u2013359. https:\/\/doi.org\/10.3390\/molecules13020348","journal-title":"Molecules"},{"key":"9715_CR33","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1016\/j.bmcl.2008.04.001","volume":"18","author":"A Melman","year":"2008","unstructured":"Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, Jacobson KA (2008) Design of (N)-methanocarba adenosine 5\u2032-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett 18:2813\u20132819","journal-title":"Bioorg Med Chem Lett"},{"key":"9715_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, Read KD, Wetsel WC, Gilbert IH, Roth BL, Hopkins AL (2012) Automated design of ligands to polypharmacological profiles. Nature 492:215\u2013220","journal-title":"Nature"},{"issue":"6","key":"9715_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214534","volume":"14","author":"P Gupta","year":"2019","unstructured":"Gupta P, Sata TN, Yadav AK, Mishra A, Vats N, Hossain MM, Sanal MG, Venugopal SK (2019) TGF-\u03b2 induces liver fibrosis via miRNA-181a-mediated down regulation of augmenter of liver regeneration in hepatic stellate cells. PLoS One 14(6):e0214534. https:\/\/doi.org\/10.1371\/journal.pone.0214534","journal-title":"PLoS One"},{"issue":"11","key":"9715_CR36","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.ajpath.2019.07.019","volume":"189","author":"DC Rockey","year":"2019","unstructured":"Rockey DC, Du Q, Shi Z (2019) Smooth muscle \u03b1-actin deficiency leads to decreased liver fibrosis via impaired cytoskeletal signaling in hepatic stellate cells. Am J Pathol 189(11):2209\u20132220. https:\/\/doi.org\/10.1016\/j.ajpath.2019.07.019","journal-title":"Am J Pathol"},{"key":"9715_CR37","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3892\/ijmm.2016.2766","volume":"38","author":"K Yokohama","year":"2016","unstructured":"Yokohama K, Fukunishi S, Ii M, Nakamura K, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K (2016) Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice. Int J Mol Med 38:1499\u20131506. https:\/\/doi.org\/10.3892\/ijmm.2016.2766","journal-title":"Int J Mol Med"},{"key":"9715_CR38","first-page":"4849","volume":"34","author":"K Takakura","year":"2014","unstructured":"Takakura K, Koido S, Fujii M, Hashiguchi T, Shibazaki Y, Yoneyama H, Katagi H, Kajihara M, Misawa T, Homma S, Ohkusa T, Tajiri H (2014) Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice. Anticancer Res 34:4849\u20134855","journal-title":"Anticancer Res"},{"issue":"18","key":"9715_CR39","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3748\/wjg.v24.i18.1989","volume":"24","author":"K Takakura","year":"2018","unstructured":"Takakura K, Oikawa T, Tomita Y, Mizuno Y, Nakano M, Saeki C, Torisu Y, Saruta M (2018) Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma. World J Gastroenterol 24(18):1989\u20131994. https:\/\/doi.org\/10.3748\/wjg.v24.i18.1989","journal-title":"World J Gastroenterol"},{"key":"9715_CR40","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1038\/s41598-019-40322-1","volume":"9","author":"JG Park","year":"2019","unstructured":"Park JG, Mok JS, Han YI, Park TS, Kang KW, Choi CS, Park HD, Park J (2019) Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. Sci Rep 9:4003. https:\/\/doi.org\/10.1038\/s41598-019-40322-1","journal-title":"Sci Rep"},{"issue":"12","key":"9715_CR41","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1124\/dmd.111.040147","volume":"39","author":"TL Farrell","year":"2011","unstructured":"Farrell TL, Dew TP, Poquet L, Hanson P, Williamson G (2011) Absorption and metabolism of chlorogenic acids in cultured gastric epithelial monolayers. Drug Metab Dispos 39(12):2338\u20132346","journal-title":"Drug Metab Dispos"},{"key":"9715_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2017","unstructured":"Bedossa P (2017) Pathology of non-alcoholic fatty liver disease. Liver Int 37:85\u201389","journal-title":"Liver Int"},{"key":"9715_CR43","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1021\/acs.jmedchem.9b01701","volume":"63","author":"FA Romero","year":"2020","unstructured":"Romero FA, Jones C, Xu Y, Fenaux M, Halcomb RL (2020) The race to bash NASH: emerging targets and drug development in a complex liver disease. J Med Chem 63:5031\u20135073","journal-title":"J Med Chem"},{"key":"9715_CR44","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K (2017) Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today 22:1707\u20131718. https:\/\/doi.org\/10.1016\/j.drudis.2017.06.007","journal-title":"Drug Discov Today"},{"issue":"5","key":"9715_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194568","volume":"13","author":"DC Oniciu","year":"2018","unstructured":"Oniciu DC, Hashiguchi T, Shibazaki Y, Bisgaier CL (2018) Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM\u2122 model of NASH. PLoS One 13(5):e0194568. https:\/\/doi.org\/10.1371\/journal.pone.0194568","journal-title":"PLoS One"},{"key":"9715_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/hep.24376","volume":"54","author":"AJ Sanyal","year":"2011","unstructured":"Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A (2011) Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54:344\u2013353","journal-title":"Hepatology"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-020-09715-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-020-09715-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-020-09715-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T23:51:02Z","timestamp":1627343462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-020-09715-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["9715"],"URL":"https:\/\/doi.org\/10.1007\/s11302-020-09715-0","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All other authors claim no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were conducted in accordance with the International Association for the Study of Pain, the National Institutes of Health guidelines on laboratory animal welfare guidelines, and the approval of Saint Louis University and NIDDK Institutional Animal Care and Use Committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}